340,974 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Bought by Toronto Dominion Bank

Toronto Dominion Bank acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 340,974 shares of the company's stock, valued at approximately $13,162,000. Toronto Dominion Bank owned approximately 0.57% of Protagonist Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PTGX. GF Fund Management CO. LTD. purchased a new position in Protagonist Therapeutics during the fourth quarter worth approximately $48,000. Covestor Ltd raised its stake in Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after purchasing an additional 1,612 shares during the period. KBC Group NV raised its position in shares of Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after buying an additional 737 shares during the period. New Vernon Capital Holdings II LLC purchased a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at approximately $118,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after buying an additional 295 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research report on Monday, May 19th. Wall Street Zen lowered Protagonist Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. JMP Securities reiterated a "market outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. Finally, BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $65.44.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CFO Asif Ali sold 24,903 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the transaction, the chief financial officer now directly owns 62,821 shares in the company, valued at approximately $3,689,477.33. This represents a 28.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the transaction, the director now owns 13,130 shares in the company, valued at $712,302.50. This trade represents a 23.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,173 shares of company stock worth $3,461,180. Corporate insiders own 4.90% of the company's stock.

Protagonist Therapeutics Price Performance

PTGX traded down $0.30 during trading on Friday, reaching $47.28. 787,365 shares of the stock were exchanged, compared to its average volume of 883,610. Protagonist Therapeutics, Inc. has a 1 year low of $27.60 and a 1 year high of $60.60. The business's 50 day moving average price is $45.24 and its two-hundred day moving average price is $42.61. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of 17.77 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.